SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-016902
Filing Date
2022-11-08
Accepted
2022-11-08 16:44:15
Documents
54
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q anvs-20220930x10q.htm   iXBRL 10-Q 802507
2 EX-31.1 anvs-20220930xex31d1.htm EX-31.1 13514
3 EX-31.2 anvs-20220930xex31d2.htm EX-31.2 13551
4 EX-32.1 anvs-20220930xex32d1.htm EX-32.1 5713
5 EX-32.2 anvs-20220930xex32d2.htm EX-32.2 5702
  Complete submission text file 0001558370-22-016902.txt   3449017

Data Files

Seq Description Document Type Size
6 EX-101.SCH anvs-20220930.xsd EX-101.SCH 28802
7 EX-101.CAL anvs-20220930_cal.xml EX-101.CAL 20924
8 EX-101.DEF anvs-20220930_def.xml EX-101.DEF 88348
9 EX-101.LAB anvs-20220930_lab.xml EX-101.LAB 256896
10 EX-101.PRE anvs-20220930_pre.xml EX-101.PRE 174461
48 EXTRACTED XBRL INSTANCE DOCUMENT anvs-20220930x10q_htm.xml XML 488064
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

IRS No.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39202 | Film No.: 221369574
SIC: 2834 Pharmaceutical Preparations